BRANDL TALOS advised shareholders of Allcyte on sale to Exscientia

Press release • Corporate Law & Transactions from Roman Rericha, Stephan Strass

Exscientia, a leading clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The transaction is subject to customary regulatory approvals.

The BRANDL TALOS deal team consisted of partner Roman Rericha, attorney Stephan Strass and associate Céline Dobnikar.

Pioneering work by Allcyte has delivered the first clinically validated platform that uses an A.I.-based screening technique to match patients with effective cancer treatments. Therefore, it is possible to select the most promising drug candidates for clinical development to maximize clinical study success rates and patient beneﬁt.

Exscientia, is a U.K. AI-driven pharmatech company that earned accolades as the world’s first company to progress AI-designed small molecules into the clinical setting. The Allcyte transaction comes shortly after Exscientia announced it had received $225 million in Series D venture capital funding from investors that include, among others, SoftBank’s Vision Fund 2, funds managed by BlackRock and Mubadala Investment Co.

By joining Exscientia, Allcyte’s platform will be significantly expanded and extended into early discovery.

» We are incredibly excited about the opportunity to immediately apply this technology to a wide range of drug discovery projects at Exscientia. We were very pleased with the work of BRANDL TALOS. Roman, Stephan and team extensively supported us in the exit process, were extremely reliable and incredibly focussed. It was a pleasure working with them and I am looking forward to many further projects. «

Nikolaus Krall, Founder and CEO of Allcyte

» This transaction again shows our expertise in the biotech sector. It is a great success story for the Austrian biotech scene and we are excited to be part of that story,” added Roman Rericha, partner at BRANDL TALOS. «

Roman Rericha

Exscientia was advised by Cooley LLP and Kunz Wallentin. SMP (Frederik Gärtner) acted as advisor to the investors.

The team

Roman Rericha

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Fund Formation, Venture Capital & Start Ups, Corporate Law & Transactions

Roman represents clients in complex cross-border M&A and private equity transactions. Austrian and international venture capital funds regularly turn to him for assisting with investments in Austria. His expert advice also guides start-ups through large-scale financing rounds.

University of Vienna, Faculty of Law (Mag. iur. 2005),
Faculty of Business, Economics and Statistics, (Mag. rer.soc.oec. 2007)

Stephan Strass

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 17
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience

Stephan advises innovative start-ups, institutional and strategic investors and other companies on acquisitions, financing rounds, joint ventures and exit transactions with a focus on highly regulated industries such as life sciences, biotech and leisure & entertainment. He further specializes in commercial transactions in the life science and biotech sector, including university spin-offs, strategic collaborations, patent and technology license agreements and IP purchase transactions.

He has co-authored commentaries on the EU Merger Act and the Investment Fund Act, and is the author of many academic publications.

University of Vienna, Faculty of Law (Mag. iur. 2015)
Harvard Law School, Master of Laws (LL.M. 2019)

Latest insights into
Corporate Law & Transactions

BRANDL TALOS advised DirectSens on the sale of its market-leading LactoSens® biosensor technology to Kerry Group

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass

Founded in 2013 in Vienna by Christoph Sygmund, Roman Kittl, Roland Ludwig, Wolfgang Harreither and Alfons Felice as a spinoff of BOKU University, DirectSens specializes in developing biosensors, including LactoSens®, a rapid lactose detection tool. The acquisition of LactoSens® by Kerry Group reflects DirectSens' success in developing cutting-edge biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes.

BRANDL TALOS advises Tipico on Sale of U.S. Sportsbook and Online Casino Platform to MGM Resorts International

Press release • Corporate Law & Transactions from Thomas Talos, Stephan Strass, Daniel Habich

Tipico entered into an agreement to sell its U.S. sportsbook and casino platform to LeoVegas group, a subsidiary of MGM Resorts International (NYSE: MGM).

BRANDL TALOS advises Pride Capital Partners on the acquisition of a minority stake in RUBICON alongside RSM Ebner Stolz

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass, Adrian Zuschmann

Pride Capital Partners, with offices in Amsterdam, Cologne, and Copenhagen, is a hybrid private equity & debt investor focusing on the software and IT industry. With the acquisition of a minority stake in Vienna-based RUBICON Group, Pride completes its first Austrian investment.